Cited by 379Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas

Open access
Izeradjene, Kamel, Combs, Chelsea, Best, Melissa, Gopinathan, Aarthi, Wagner, Amary, Grady, William M., Deng, Chu-Xia, Hruban, Ralph H. +3 more·2007·Cancer Cell

Abstract

Oncogenic Kras initiates pancreatic tumorigenesis, while subsequent genetic events shape the resultant disease. We show here that concomitant expression of Kras(G12D) and haploinsufficiency of the Smad4/Dpc4 tumor suppressor gene engenders a distinct class of pancreatic tumors, mucinous cystic neoplasms (MCNs), which culminate in invasive ductal adenocarcinomas. Disease evolves along a progression scheme analogous to, but distinct from, the classical PanIN-to-ductal adenocarcinoma sequence, and also portends a markedly different prognosis. Progression of MCNs is accompanied by LOH of Dpc4 and mutation of either p53 or p16. Thus, these distinct phenotypic routes to invasive adenocarcinoma nevertheless share the same overall mutational spectra. Our findings suggest that the sequence, as well as the context, in which these critical mutations are acquired helps determine the ensuing pathology.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2007.01.017

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Combined haploinsufficiency of Smad4 with oncogenic KRAS expression leads to cystic neoplasms in mice, linking Kras mutations to putative PDAC precursor lesions.

    “the combined haploinsufficiency of Smad4, coupled with oncogenic KRAS expression, leads to the development of cystic neoplasms, linking Kras mutations to other putative PDAC precursor lesions33.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [33]

The citation lists haven’t been fetched yet

References 55 · Cited by 379

Authors
Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A., & Hingorani, S. R.
Affiliations
  • University of Washington (US)
  • Abramson Cancer Center (US)
  • Fred Hutch Cancer Center (US)
  • National Institutes of Health (US)
  • Johns Hopkins University (US)
Corresponding author
Hingorani, Sunil R.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2007-03
Volume
11
Issue
3
Pages
229-243
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2122441872
Cited by
379
References
55
Citations by year
2026: 7 · 2025: 7 · 2024: 14 · 2023: 18 · 2022: 14 · 2021: 25 · 2020: 22 · 2019: 22 · 2018: 25 · 2017: 22 · 2016: 19 · 2015: 17 · 2014: 23 · 2013: 22 · 2012: 18
FWCI
12.65
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA 15704, P50CA-62924, U01CA084291, R01CA101973, P50CA062924, P30CA015704)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
KRAS G12D, SMAD4, haploinsufficiency, mucinous cystic neoplasm, pancreatic ductal adenocarcinoma, pancreatic carcinogenesis, tumor suppressor, loss of heterozygosity, TP53 mutation, p16 mutation, tumor progression, prognosis, mutational spectra
MeSH terms
Animals, Disease Models, Animal, Haplotypes, Humans, Mice, Mutant Strains, Mutation, Neoplasm Invasiveness, Pancreatic Neoplasms, Prognosis, Genes, ras, Signal Transduction, Tumor Suppressor Protein p53, Transforming Growth Factor beta, Cystadenoma, Mucinous, Cyclin-Dependent Kinase Inhibitor p16, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, Mice, Smad4 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review